Candriam S.C.A. Allogene Therapeutics, Inc. Transaction History

Candriam S.C.A.

  • $17.1 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Jan 22, 2021
SELL
$25.24 - $43.45 $1.68 Million - $2.89 Million
-66,561 Closed
0 $0
Q3 2020

Oct 19, 2020
SELL
$32.38 - $44.96 $44,231 - $61,415
-1,366 Reduced 2.01%
66,561 $2.51 Million
Q2 2020

Jul 23, 2020
BUY
$18.39 - $54.04 $1.25 Million - $3.67 Million
67,927 New
67,927 $2.91 Million

Others Institutions Holding ALLO

# of Institutions
162
Shares Held
134M
Call Options Held
46.4K
Put Options Held
113K
View Full List

About Allogene Therapeutics, Inc.

ALLO Quotes by TradingView
  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $354M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email